EUVIMEDEUVIMED entdecken
Crossref

Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice

María José Germanó, Constanza Giai, Diego Esteban Cargnelutti, María Isabel Colombo, Sebastián Blanco iD, Brenda Konigheim, Lorena Spinsanti, Javier Aguilar, Sandra Gallego, Hugo Alberto Valdez, Juan Pablo Mackern-Oberti, Maria Victoria Sanchez

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28584 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von María José Germanó und 11 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Medicina y Biología Experimental de Cuyo, Centro Científico Tecnológico, Consejo Nacional de Investigaciones Científicas y Técnicas (CON…. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel adjuvants are highly desired to improve immune responses of SARS‐CoV‐2 vaccines. This work reports the potential of the stimulator of interferon genes (STING) agonist adjuvant, the cyclic di‐adenosine monophosphate (c‐di‐AMP), in a SARS‐CoV‐2 vaccine based on the receptor binding domain (RBD). Here, mice immunized with two doses of monomeric RBD adjuvanted with c‐di‐AMP intramuscularly were found to exhibit stronger immune responses compared to mice vaccinated with RBD adjuvanted with aluminum hydroxide (Al(OH) 3 ) or without adjuvant. After two immunizations, consistent enhancements in the magnitude of RBD‐specific immunoglobulin G (IgG) antibody response were observed by RBD + c‐di‐AMP (mean: 15360) compared to RBD + Al(OH) 3 (mean: 3280) and RBD alone (n.d.). Analysis of IgG subtypes indicated a predominantly Th1‐biased immune response (IgG2c, mean: 14480; IgG2b, mean: 1040, IgG1, mean: 470) in mice vaccinated with RBD + c‐di‐AMP compared to a Th2‐biased response in those vaccinated with RBD + Al(OH) 3 (IgG2c, mean: 60; IgG2b: n.d.; IgG1, mean: 16660). In addition, the RBD + c‐di‐AMP group showed better neutralizing antibody responses as determined by pseudovirus neutralization assay and by plaque reduction neutralization assay with SARS‐CoV‐2 wild type. Moreover, the RBD + c‐di‐AMP vaccine promoted interferon‐γ secretion of spleen cell cultures after RBD stimulation. Furthermore, evaluation of IgG‐antibody titers in aged mice showed that di‐AMP was able to improve RBD‐immunogenicity at old age after 3 doses (mean: 4000). These data suggest that c‐di‐AMP improves immune responses of a SARS‐CoV‐2 vaccine based on RBD, and would be considered a promising option for future COVID‐19 vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19AnimalsMiceHumansSARS-CoV-2Adjuvants, ImmunologicImmunity, CellularAntibodies, NeutralizingAdjuvants, PharmaceuticImmunoglobulin GAdenosine MonophosphateAntibodies, ViralSpike Glycoprotein, CoronavirusImmunity, Humoral

Stichwörter der Autor:innen

SARS-CoV-2adjuvantc-di-AMPimmune responsevaccines

Substanzen

COVID-19 VaccinesAdjuvants, ImmunologicAntibodies, NeutralizingAdjuvants, PharmaceuticImmunoglobulin GAdenosine MonophosphateAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Instituto de Medicina y Biología Experimental de Cuyo, Centro Científico Tecnológico, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)-Mendoza, Universidad Nacional de Cuyo, Mendoza, Argentina.
  • Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
  • Instituto de Histología y Embriología de Mendoza, CONICET-Mendoza, Universidad Nacional de Cuyo-(UNCuyo) CONICET, Mendoza, Argentina.
  • Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
  • Instituto de Virología "Dr. J. M. Vanella" (InViV), Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
  • Centro de Investigación y Desarrollo en Fermentaciones Industriales (CINDEFI), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina.

ORCID-Profile: Sebastián Blanco

Zitieren

APA

Germanó, M. J., Giai, C., Cargnelutti, D. E., Colombo, M. I., Blanco, S., Konigheim, B., Spinsanti, L., Aguilar, J., Gallego, S., Valdez, H. A., Mackern-Oberti, J. P., & Sanchez, M. V. (2023). Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice. Journal of Medical Virology. https://doi.org/10.1002/jmv.28584

Vancouver

Germanó MJ, Giai C, Cargnelutti DE, Colombo MI, Blanco S, Konigheim B, et al. Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice. Journal of Medical Virology. 2023. doi:10.1002/jmv.28584

BibTeX
@article{German2023,
  author = {Germanó, María José and Giai, Constanza and Cargnelutti, Diego Esteban and Colombo, María Isabel and Blanco, Sebastián and Konigheim, Brenda and Spinsanti, Lorena and Aguilar, Javier and Gallego, Sandra and Valdez, Hugo Alberto and Mackern-Oberti, Juan Pablo and Sanchez, Maria Victoria},
  title = {Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28584}
}
Kostenlos starten →